One Case of Hepatic Dysfunction Induced by Olaparib Tablets

doi:10.19803/j.1672-8629.2019.12.12

Abstract

CLC Number:

R994.11

XU Yinying, JIANG Sunmin. One Case of Hepatic Dysfunction Induced by Olaparib Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 762-764.

[1] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南[J].中华肝脏病杂志, 2015, 23(10):1752-1769.
[2] 刘建平, 邢建民. 循证的药品不良反应评价方法[J]. 中国药物警戒, 2010, 7(1):12-15.
[3] Moore Kathleen, Colombo Nicoletta, Scambia Giovanni,et al.Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer[J]. N Engl J Med, 2018, 379(26):2495-2505.
[4] Friedlander Michael, Matulonis Ursula, Gourley Charlie,et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy[J]. Br J Cancer,2018, 119(9):1075-1085.
[5] Moore K N, Monk B J.Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer[J]. Oncologist, 2016, 21(8):954-63.
[6] Pujadelauraine E, Ledermann J A, Selle F, et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive,relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(9):1274-1284.
[7] Robson Mark, Im Seock-Ah, Senkus Elżbieta, et al.Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J]. N Engl J Med, 2017,377(6): 523-533.
[8] Bang Yung-Jue, Xu Rui-Hua, Chin Keisho, et al.Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12):1637-1651.
[9] Ledermann Jonathan A, Harter Philipp, Gourley Charlie,et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib main tenance monotherapy: an updated analysis from a randomised,placebo-controlled, double-blind, phase 2 trial[J]. Lancet Oncol, 2016, 17(11): 1579-1589.
[10] Oza Amit M, Cibula David, Benzaquen Ana Oaknin, et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial[J]. Lancet Oncol, 2015, 16(1):87-97.
[11] Kaufman B, Shapirafrommer R, Schmutzler R K, et al.Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation[J]. J Clin Oncol,2015, 33(3):244-50.
[12] Domchek S M, Aghajanian C, Shapira-Frommer R, et al.Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy[J]. Gynecol Oncol,2016, 140(2):199-203.
[13] Liu J F, Barry W T, Birrer M, et al.Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study[J]. Lancet Oncol, 2014, 15(11):1207-1214.
[14] Del Conte G, Sessa C, Von Moos R, et al.Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours[J]. Br J Cancer, 2014, 111(4):651-659.
[15] Balmana J, Tung N M, Isakoff S J, et al.Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors[J]. Ann Oncol, 2014, 25(8):1656-1663.
[16] Choy Edwin, Butrynski James E, Harmon David C, et al.Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy[J].BMC Cancer, 2014, 14(1):1-6.
[17] Ledermann Jonathan, Harter Philipp, Gourley Charlie, et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J]. Lancet Oncol, 2014, 15(8):852-861.
[18] Sandhu S K, Omlin A, Hylands L, et al.Poly (ADP-ribose)polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer[J]. Ann Oncol,2013, 24(5):1416-1418.
[19] Samol J, Ranson M, Scott E, et al.Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study[J].Invest New Drugs, 2012, 30(4):1493-1500.
[20] Ledermann J, Harter P, Gourley C, et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer[J].N Engl J Med, 2012, 366(15):1382-1392.
[21] Kaye S B, Lubinski J, Matulonis U, et al.Phase II, open-label,randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor,and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer[J]. J Clin Oncol, 2012, 30(4):372-379.
[22] Khan O A, Gore M, Lorigan P, et al.A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436)and dacarbazine in patients with advanced solid tumours[J].Br J Cancer, 2011, 104(5):750-755.
[23] Liu J, Fleming G F, Tolaney S M, et al.A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer[J]. J Clin Oncol, 2011, 29(15):5028-5028.

One Case of Hepatic Dysfunction Induced by Olaparib Tablets

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131.
[2]	ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136.
[3]	BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140.
[4]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[5]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[6]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[7]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[8]	WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
[9]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[10]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[11]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[12]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[13]	LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
[14]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[15]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.